The OJC Episode 28: ASCO GU Roundtable
Eva Segelov and Craig Underhill are joined by Philip Parente and Carmel Pezaro for this…
Browsing: Olaparib
Study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer
Studies have shown that utilising a PARP inhibitor in the management of patients with metastatic…
Prostate cancer drug targeting Achilles heel approved in Europe
The Institute of Cancer Research, London, UK, has strongly welcomed the approval by the European…
Olaparib approved in Europe for prostate cancer
The Institute of Cancer Research, London, UK, has strongly welcomed the approval by the European…
ESMO 2020: Step forward in treatment for patients with newly diagnosed advanced ovarian cancer
Almost half of patients who received a targeted drug during treatment for newly diagnosed BRCA-mutated…
ESMO 2020: PARP inhibitor olaparib for the targeted treatment of metastatic prostate cancer
Results from the PROfound phase III study, funded by AstraZeneca and Merck Sharp & Dohme,…
Combining two precision medicines can treat drug-resistant cancers
Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could…
Breast cancer drug, olaparib, depletes store of immature eggs in mouse ovaries
Australian researchers have shown for the first time that a new drug used to treat…
ASCO 2020: Combined cediranib and olaparib presents similar activity to standard of care treatment
Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of…
FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer
On May 19, 2020, the Food and Drug Administration approved olaparib for adult patients with…